The decision to discontinue BTK inhibitor treatment for CLL is complex, with emerging data suggesting that time-limited ...

The BTK inhibitors market has experienced significant dynamics driven by advancements in oncology and autoimmune disease ...

Sanofi released new Phase 3 data for its BTK inhibitor tolebrutinib in non-relapsing secondary progressive multiple sclerosis ...

Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate ...

The positive readout in patients with non-relapsing secondary progressive multiple sclerosis comes on the heels of ...

The totality of data from Sanofi clinical trials indicates that Tolebrutinib may target inflammation thought to contribute to ...

Treatment with Brukinsa may lower the rates of switching therapies compared with Calquence and Imbruvica in chronic ...

Roche’s fenebrutinib this week scored a mid-stage win in relapsing multiple sclerosis, while Sanofi’s tolebrutinib met the ...

Roche has three ongoing Phase III trials of its BTK inhibitor fenebrutinib in patients with relapsing multiple sclerosis.

Data from the HERCULES trial presented at the ECTRIMS conference in Copenhagen, Denmark, today showed that tolebrutinib was ...

The BTK inhibitors market is poised for remarkable growth driven by advancements in oncology and autoimmune disease treatments. With expanding research and development efforts, these inhibitors ...

The Bruton's tyrosine kinase inhibitor tolebrutinib is reportedly the first agent to show benefit in patients with nonrelapsing secondary progressive MS.